Press ReleaseAIMHI_wpuser2024-08-29T11:16:30+00:00

Press Release

Press Release

Making Cancer Patient Clinical Trial Recruitment & Engagement Easier

AIMHI_wpuser2025-02-21T15:59:42+00:00June 9, 2021|Press Release|

Privo Technologies, Inc. to Present Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the Upcoming 2021 ASCO Annual Meeting

AIMHI_wpuser2025-02-21T16:00:07+00:00June 3, 2021|Press Release|

TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer

AIMHI_wpuser2025-02-21T16:00:07+00:00May 10, 2021|Press Release|

Applications Open for the 2021 AIM-HI Women’s Venture Competition!

AIMHI_wpuser2025-02-21T16:00:08+00:00March 8, 2021|Press Release|

Winner of the AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition Announced

AIMHI_wpuser2025-02-21T16:00:08+00:00February 22, 2021|Press Release|

Oncoheroes & SHEPHERD Therapeutics United Against Rare Cancers

AIMHI_wpuser2025-02-21T16:00:08+00:00February 15, 2021|Press Release|

Previous 678 Next

AIMhi

AIM-HI Accelerator Fund is a 501(c)(3) tax-exempt nonprofit organization.

Tax ID #: 82-4322538

Address:

5515 Security Lane, Suite 1105
Rockville, MD 20852

Email:

info@aim-hiaccelerator.org

Phone:

1-800-321-CURE (2873)

what we do

Copyright © AIM-HI 2025 All Rights Reserved

AIMhi

AIM-HI Accelerator Fund is a 501(c)(3) tax-exempt nonprofit organization.

Tax ID #: 82-4322538

Copyright © AIM-HI 2025 All Rights Reserved